- Home
- XNCR vs ELVN Comparison
XNCR vs ELVN Comparison
Compare XNCR & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XNCR | ELVN |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XNCR | ELVN |
|---|---|---|
| Price | $15.28 | $16.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $22.78 | ★ $41.00 |
| AVG Volume (30 Days) | 761.7K | ★ 798.5K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $150,132,000.00 | N/A |
| Revenue This Year | $18.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 38.16 | N/A |
| 52 Week Low | $6.92 | $13.30 |
| 52 Week High | $24.91 | $25.37 |
Technical Indicators
Market Signals| Indicator | XNCR | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 37.75 |
| Support Level | $14.97 | $15.71 |
| Resistance Level | $16.17 | $18.05 |
| Average True Range (ATR) | 0.77 | 1.39 |
| MACD | -0.28 | -0.19 |
| Stochastic Oscillator | 10.81 | 10.61 |
Price Performance
Historical ComparisonAbout XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.